financetom
Business
financetom
/
Business
/
Ross Stores lifts annual profit forecast on lower costs, shares rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ross Stores lifts annual profit forecast on lower costs, shares rise
Nov 21, 2024 6:55 PM

(Reuters) - Off-price retailer Ross Stores ( ROST ) raised its annual profit forecast on Thursday, as lower freight and supply-chain costs helped soften the impact of slowing sales at its stores, sending its shares up 7% after the bell.

The company has also been trying to sell a wider product assortment at different price points to increasingly cautious lower-income consumers.

Still, it tempered its fourth-quarter profit forecast and its third-quarter net sales missed market expectations as consumers delayed big spending on apparel and other non-essential items.

"Although our low-to-moderate income customers continue to face persistently high costs on necessities pressuring their discretionary spending, we believe we should have better executed some of our merchandising initiatives," CEO Barbara Rentler said.

Demand for discounted apparel had led Ross' rival and Marshalls parent, TJX Cos ( TJX ), to raise its annual profit forecast earlier this week.

Retail giant Walmart also raised its annual profit and sales targets this month, betting on consumers to head to its superstores for steep discounts during the holidays.

However, Target's holiday-quarter forecast for profit and sales was below market expectations, as the retailer cautioned a promotion-heavy period.

Ross expects fourth-quarter comparable sales to increase between 2% to 3%, compared with analysts' expectations of a 2.6% rise, according to analysts polled by LSEG.

The company, which named retail veteran and former Boot Barn top boss James Conroy as its next CEO from Feb. 2, expects fourth-quarter earnings per share of $1.57 to $1.64, compared with expectations of $1.67.

Ross Stores ( ROST ) reported third-quarter sales of $5.1 billion, compared with estimates of $5.15 billion. It expects annual earnings per share of $6.10 to $6.17, compared with prior forecast of $6.00 to $6.13.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved